Skip to main content
Visit our Newsroom for the latest news and events from Takeda California
Learn about recent publications and presentations arising from our research activities
Learn more about how we demonstrate a comitment to the community, health and education.
Takeda California is Takeda's Center of Excellence and Innovation for Structure-Based Drug Discovery and Protein Therapeutics. The company combines cutting-edge protein x-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Multiple potential new drugs invented at Takeda California are in clinical trials evaluation including NESINA® (generic name Alogliptin) which was approved for treating patients with type II diabetes in Japan in 2010.
Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Together with its worldwide partners in science, Takeda California is committed to strive toward better health for patients through leading innovation in medicine.
To learn about Takeda's global operations, please visit http://www.takeda.com.